Another Day Another Anti-depressant

Another Day Another Anti-depressant

The New Year brings us another harmful psychoactive antidepressant – Brintellix (vortioxetine hydrobromide).

The mechanism of the antidepressant effect of vortioxetine is not understood, although it is theorized to be related to serotonin in the brain.

It has the same pattern of debilitating side effects as any other antidepressant, including addiction and suicidal thoughts and actions.

Developed by the Danish company H. Lundbeck A/S and marketed by Takeda Pharmaceuticals, it is an SSRI (selective serotonin reuptake inhibitor) drug. It was approved by the U.S. Food and Drug Administration in September, 2013. Its sales to date have not been inspiring, possibly related to its initial review by the National Institute for Health and Care Excellence (NICE) in the U.K. which said, “there was no convincing evidence to show that vortioxetine was any more or less effective than other antidepressants.”

Lundbeck and Takeda are making a new push to increase sales by submitting additional clinical trial data to the FDA and to NICE. You may now start seeing TV commercials for it. Don’t be fooled; there has been no change in the drug itself or its devastating withdrawal and side effects.

We must recognize that the real problem is that psychiatrists and other medical practitioners fraudulently diagnose life’s problems as an “illness” and stigmatize unwanted behavior as  “diseases.” Psychiatry’s stigmatizing labels, programs and treatments are harmful junk science; their diagnoses of “mental disorders” are a hoax – unscientific, fraudulent and harmful.

CCHR believes that everyone has the right to full informed consent.

FIND OUT! FIGHT BACK!

This entry was posted in Big Muddy River Newsletter, Press Releases and tagged , , . Bookmark the permalink.

Leave a Reply